Spots Global Cancer Trial Database for Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation
Official Title: Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA Non-small Cell Lung Cancer With EGFR-mutation: a Randomized, Positive-controlled, Phase 3 Study (EVIDENCE, CCTC-1501)
Study ID: NCT02448797
Conditions
Study Description
Brief Summary: Adjuvant therapy has been proved effective in treating earlier stage or less advanced non-small-cell lung cancer. This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in treating stage II-IIIA non-small cell lung cancer patients with EGFR mutation. The primary endpoint is disease-free survival.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
307 Hospital of PLA, Beijing, Beijing, China
Fujian Provincal Cancer Hospital, Fuzhou, Fujian, China
The First Affiliated Hospital Of Guangzhou Medical Collage, Guangzhou, Guangdong, China
Shenzhen People's Hospital, Shenzhen, Guangdong, China
The First Hospital of China Medical University, Shenyang, Liaoning, China
First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang, China
Contact Details
Name: Caicun Zhou, MD
Affiliation: Shanghai Pulmonary Hospital, Shanghai, China
Role: STUDY_CHAIR
Name: Jianxing He, MD
Affiliation: The First Affiliated Hospital of Guangzhou Medical University
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
